About Cyclerion
Cyclerion is a company based in Cambridge (United States) founded in 2018. The company has 1 employees as of December 31, 2024. Cyclerion offers products and services including Biofeedback Delivery Device and TRD Therapy. Cyclerion operates in a competitive market with competitors including Editas Medicine, GBT, LogicBio, Kedrion and Modus Therapeutics, among others.
- Headquarter Cambridge, United States
- Employees 1 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cyclerion Therapeutics, Inc.
-
Annual Revenue
$2 M (USD)0as on Dec 31, 2024
-
Net Profit
-$3.06 M (USD)85.45as on Dec 31, 2024
-
EBITDA
-$3.63 M (USD)62.39as on Dec 31, 2024
-
Latest Funding Round
$18.03 M (USD), Post-IPO
Jun 04, 2021
-
Investors
Alzheimer’s Association
& 7 more
-
Employee Count
1
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Cyclerion
Cyclerion is a publicly listed company on the NASDAQ with ticker symbol CYCN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Cyclerion
Cyclerion offers a comprehensive portfolio of products and services, including Biofeedback Delivery Device and TRD Therapy.
Delivers anesthetics for treating depression via personalized biofeedback.
Innovative therapy targeting treatment-resistant depression through technology.
People of Cyclerion
Unlock access to complete
Funding Insights of Cyclerion
Investors in Cyclerion
Cyclerion has secured backing from 8 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Alzheimer’s Association, EcoR1 and Slate Path Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Long-term private equity investments in transformational opportunities are pursued.
|
Locked | Locked | Locked | |
|
Private equity investments are directed toward North American opportunities.
|
Locked | Locked | Locked | |
|
US focused venture capital firm
|
Locked | Locked | Locked |
Investor details for Cyclerion
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cyclerion
Investment portfolio details for Cyclerion
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cyclerion
Detailed financials for Cyclerion
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cyclerion Comparisons
Peer comparison for Cyclerion
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cyclerion
Cyclerion operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Editas Medicine, GBT, LogicBio, Kedrion and Modus Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for rare genetic diseases are developed using CRISPR technology.
|
|
| Locked | Locked | Locked |
Small molecules are developed for sickle cell disease treatment.
|
|
| Locked | Locked | Locked |
Viral vectors are developed for genetic and infectious disease treatments.
|
|
| Locked | Locked | Locked |
Plasma-derived therapies are developed for hemophilia and immune deficiencies.
|
|
| Locked | Locked | Locked |
Polysaccharide-based drug for Sickle Cell Disease treatment is developed.
|
Detailed competitors of Cyclerion
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cyclerion
Complete news archive for Cyclerion
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cyclerion
Cyclerion was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Cyclerion is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
As of Dec 31, 2024, the latest employee count at Cyclerion is 1.
Annual revenue of Cyclerion is $2M as on Dec 31, 2024.
Cyclerion is involved in developing therapies for treating sickle cell disease (SCD) and diabetic nephropathy. They are focussed on the nitric oxide-cyclic guanosine monophosphate (cGMP) signaling pathway. Their lead candidate, Olinciguat, which is a vascular guanylate cyclase agonist. The candidate is in phase II clinical trial. They have granted Orphan Drug Designation for SCD by the U.S. Food and Drug Administration.
Cyclerion's top competitors include GBT, Editas Medicine and Kedrion.
Cyclerion offers Biofeedback Delivery Device and TRD Therapy.
Yes, Cyclerion is publicly traded on NASDAQ under the ticker symbol CYCN.
Cyclerion has 8 investors. Key investors include Alzheimer’s Association, EcoR1, Slate Path Capital, Invus, and Peter Hecht.
The ticker symbol of Cyclerion is CYCN on NASDAQ.